beta cell replacement in IDDM by transplantation of either isolated adult i
slets of Langerhans or of proliferating immature islet tissue from fetal pa
ncreas are potential ways of curing this disease. Because of the dearth of
human cadaver donors adult allogeneic islets are scarce and in most Western
societies availability of human fetal tissue of suitable maturity is also
uncommon. The use of xenogeneic islets from domestic species already widely
used for human consumption, e.g. pigs, could overcome this scarcity but xe
nogeneic tissues are faced with major problems of graft rejection. Hyperacu
te rejection (HAR) is the main cause of destruction of immediately vascular
ised xenografts and is caused by the interaction of natural cross-reactive
antibodies with donor endothelial cells. Neovascularized islet grafts do no
t have donor EC as the target for HAR and are not subjected to this problem
but are still acutely rejected. The mechanism of this destruction is still
poorly understood but is clearly T cell dependent. However, current immuno
suppression that is usually adequate for control of allograft rejection gen
erally does not prevent xenograft rejection. A better understanding of the
ways in which xenoantigens are recognised and of the nature of the immune r
esponse they initiate is fundamental to the development of appropriate stra
tegies for the safe and effective control of xenograft rejection. The studi
es summarized herein describe the response of mice and primates to a challe
nge with fetal pig pancreas grafts, The rejection response that develops is
different from that seen against a challenge with fetal allogeneic islets.
Although the xenograft response is highly T cell dependent the actual effe
cters of graft damage appear to be different from those that provoke allogr
aft destruction and include macrophages and granulocytes, particularly eosi
nophils, and possibly non-classical T cells.